Menu

InSphero and DefiniGEN Receive Eurostars Grant to Develop Human Stem Cell-derived Screening Platform for Diabetes Drug Discovery

InSphero and DefiniGEN Receive Eurostars Grant to Develop Human Stem Cell-derived Screening Platform for Diabetes Drug Discovery

24th September 2019

InSphero and DefiniGEN Receive Eurostars Grant to Develop Human Stem Cell-derived Screening Platform for Diabetes Drug Discovery New platform to combine stem cell and CRISPR gene-editing technology with proven 3D cell culture techniques for producing standardized pancreatic islet disease models Schlieren, Switzerland and Cambridge, UK– September 24, 2019  InSphero AG and DefiniGEN Ltd. today announced […]

ERS Genomics CRISPR License Agreement | DefiniGEN

ERS Genomics CRISPR License Agreement | DefiniGEN

4th January 2019

DUBLIN, Ireland, and CAMBRIDGE, UK, November 1, 2018 – ERS Genomics Limited and DefiniGEN Ltd announced today a license agreement to provide DefiniGEN with access to ERS Genomic’s CRISPR/Cas9 genome editing technology patents. DefiniGEN will combine their best-in-class iPSC (induced Pluripotent Stem Cell) differentiation platform with CRISPR/Cas9 technology to generate a range of innovative preclinical […]